Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MCF12A | NM | Basal B | Nilotinib | ABL | nRTK | 8 | uM | 10817.145 | 0.9869 | 0.9831 | 1.5564 | |
| MCF12A | NM | Basal B | Nilotinib | ABL | nRTK | 40 | uM | 10817.145 | 0.9656 | 0.9556 | 1.5564 | |
| MCF12A | NM | Basal B | Nilotinib | ABL | nRTK | 200 | uM | 10817.145 | 1.0062 | 1.0080 | 1.5564 | |
| MCF12A | NM | Basal B | Nilotinib | ABL | nRTK | 0.000512 | uM | 12365.17 | 0.9332 | 0.9406 | 2.2930 | |
| MCF12A | NM | Basal B | Nilotinib | ABL | nRTK | 0.00256 | uM | 12365.17 | 0.8417 | 0.8552 | 2.2930 | |
| MCF12A | NM | Basal B | Nilotinib | ABL | nRTK | 0.0128 | uM | 12365.17 | 0.8928 | 0.9035 | 2.2930 | |
| MCF12A | NM | Basal B | Nilotinib | ABL | nRTK | 0.064 | uM | 12365.17 | 0.9371 | 0.9441 | 2.2930 | |
| MCF12A | NM | Basal B | Nilotinib | ABL | nRTK | 0.32 | uM | 12365.17 | 0.9574 | 0.9624 | 2.2930 | |
| MCF12A | NM | Basal B | Nilotinib | ABL | nRTK | 1.6 | uM | 12365.17 | 0.9392 | 0.9460 | 2.2930 | |
| MCF12A | NM | Basal B | Nilotinib | ABL | nRTK | 8 | uM | 12365.17 | 0.8444 | 0.8578 | 2.2930 | |
| MCF12A | NM | Basal B | Nilotinib | ABL | nRTK | 40 | uM | 12365.17 | 0.9272 | 0.9351 | 2.2930 | |
| MCF12A | NM | Basal B | Nilotinib | ABL | nRTK | 200 | uM | 12365.17 | 0.9162 | 0.9251 | 2.2930 | |
| MCF7 | HR+ | Luminal | Nilotinib | ABL | nRTK | 0.000512 | uM | 10997.145 | 0.9671 | 0.9526 | 1.3945 | |
| MCF7 | HR+ | Luminal | Nilotinib | ABL | nRTK | 0.00256 | uM | 10997.145 | 0.9790 | 0.9698 | 1.3945 | |
| MCF7 | HR+ | Luminal | Nilotinib | ABL | nRTK | 0.0128 | uM | 10997.145 | 0.8148 | 0.7267 | 1.3945 | |
| MCF7 | HR+ | Luminal | Nilotinib | ABL | nRTK | 0.064 | uM | 10997.145 | 0.9769 | 0.9667 | 1.3945 | |
| MCF7 | HR+ | Luminal | Nilotinib | ABL | nRTK | 0.32 | uM | 10997.145 | 0.9523 | 0.9311 | 1.3945 | |
| MCF7 | HR+ | Luminal | Nilotinib | ABL | nRTK | 1.6 | uM | 10997.145 | 0.9642 | 0.9484 | 1.3945 | |
| MCF7 | HR+ | Luminal | Nilotinib | ABL | nRTK | 8 | uM | 10997.145 | 0.9160 | 0.8780 | 1.3945 | |
| MCF7 | HR+ | Luminal | Nilotinib | ABL | nRTK | 40 | uM | 10997.145 | 1.0619 | 1.0880 | 1.3945 | |
| MCF7 | HR+ | Luminal | Nilotinib | ABL | nRTK | 200 | uM | 10997.145 | 1.0277 | 1.0396 | 1.3945 | |
| MDA-MB-134-VI | HR+ | Luminal | Nilotinib | ABL | nRTK | 0.000512 | uM | 10998.145 | 0.8974 | 0.7824 | 0.9403 | |
| MDA-MB-134-VI | HR+ | Luminal | Nilotinib | ABL | nRTK | 0.00256 | uM | 10998.145 | 0.8893 | 0.7655 | 0.9403 | |
| MDA-MB-134-VI | HR+ | Luminal | Nilotinib | ABL | nRTK | 0.0128 | uM | 10998.145 | 0.9481 | 0.8899 | 0.9403 | |
| MDA-MB-134-VI | HR+ | Luminal | Nilotinib | ABL | nRTK | 0.064 | uM | 10998.145 | 0.9039 | 0.7962 | 0.9403 |